Geode Capital Management LLC increased its holdings in Renovaro Inc. (NASDAQ:RENB - Free Report) by 48.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,332,634 shares of the company's stock after acquiring an additional 760,344 shares during the quarter. Geode Capital Management LLC owned about 1.47% of Renovaro worth $1,949,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its stake in shares of Renovaro by 280.4% in the 4th quarter. JPMorgan Chase & Co. now owns 353,833 shares of the company's stock valued at $296,000 after purchasing an additional 260,823 shares during the period. Corebridge Financial Inc. lifted its position in Renovaro by 114.8% during the fourth quarter. Corebridge Financial Inc. now owns 57,495 shares of the company's stock valued at $48,000 after buying an additional 30,727 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Renovaro by 82.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 362,126 shares of the company's stock valued at $303,000 after buying an additional 163,160 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Renovaro by 137.2% in the 4th quarter. Bank of New York Mellon Corp now owns 223,915 shares of the company's stock worth $187,000 after buying an additional 129,529 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Renovaro by 122.6% in the 4th quarter. Rhumbline Advisers now owns 112,960 shares of the company's stock worth $94,000 after acquiring an additional 62,204 shares in the last quarter. 71.41% of the stock is owned by hedge funds and other institutional investors.
Renovaro Price Performance
NASDAQ:RENB traded down $0.02 during mid-day trading on Monday, hitting $0.32. 83,319 shares of the company's stock were exchanged, compared to its average volume of 939,811. The company has a market cap of $50.15 million, a PE ratio of -0.34 and a beta of 0.63. Renovaro Inc. has a one year low of $0.30 and a one year high of $2.34. The business has a fifty day moving average price of $0.58 and a 200 day moving average price of $0.76.
Renovaro (NASDAQ:RENB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.02) earnings per share for the quarter.
Renovaro Profile
(
Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
See Also
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
